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2Summary
Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours
overexpress the ErbB2/HER2 receptor which correlates with disease progression and poor
prognosis. The mechanisms of ErbB2 signalling and the effects of its overexpression are not
fully understood. Herein, SILAC expression profiling and phosphopeptide enrichment of a
relevant, non-transformed, immortalized human mammary luminal epithelial cell model were
used to profile ErbB2-dependent differences in protein expression and phosphorylation events
triggered via EGFR (EGF treatment) and ErbB3 (HRG1 treatment) in the context of ErbB2
overexpression. Bioinformatics analysis was used to infer changes in cellular processes and
signalling events. We demonstrate the complexity of the responses to oncogene expression
and growth factor signalling and identify protein changes relevant to ErbB2-dependent altered
cellular phenotype, in particular cell cycle progression and hyper-proliferation, reduced
adhesion and enhanced motility. Moreover, we define a novel mechanism by which ErbB
signalling suppresses basal interferon signalling that would promote the survival and
proliferation of mammary luminal epithelial cells. Numerous novel sites of growth factor-
regulated phosphorylation were identified that were enhanced by ErbB2 overexpression and
we putatively link these to altered cell behaviour and also highlight the importance of
performing parallel protein expression profiling alongside phosphoproteomic analysis.
3Introduction
The expression and activity of the ErbB/HER family of receptor tyrosine kinases is frequently
deregulated in human cancers. In particular, amplification of ErbB2/HER2 in breast cancer
correlates with disease progression, poorer prognosis and recurrence (1, 2). Despite intensive
research, the molecular mechanisms of downstream ErbB receptor signalling and the effects
on normal cell behaviour and tumour progression remain ambiguous and further detailed
elucidation of ErbB-specific signalling mechanisms are essential to realising novel diagnostic
and prognostic markers and therapeutic targets.
Signalling through the ErbB family (EGFR, ErbB2, ErbB3 and ErbB4) is initiated by ligand-
induced receptor homo- and heterodimerization with subsequent activation of intrinsic tyrosine
kinase activity and receptor phosphorylation. This creates docking sites for adaptor proteins
and enzymes to initiate signal transduction leading to altered gene and protein expression and
modulation of cellular phenotype (3). Numerous tumour, epithelial or stromal-derived growth
factors bind with different affinities and specificities to the ErbB receptor family including: EGF,
amphiregulin and TGF (EGFR-specific); betacellulin and epiregulin (specific for EGFR and
ErbB4) (4); and the neuregulin/heregulin (HRG) family (specific for ErbB3 and ErbB4) (5).
ErbB2 is an orphan receptor, but preferentially dimerizes with the other family members to
potentiate signalling, whilst ErbB3 lacks intrinsic kinase activity and is reliant upon
heterodimerization for signal transduction (5, 6).
EGF and HRG activate many intracellular signalling cascades and exert distinct biological
functions, and although there is major overlap in the pathways activated, specific ErbB family
members preferentially modulate distinct pathways. For instance, while all four ErbB receptors
activate the classical MAPK pathway via Shc and/or Grb2, ErbB3 is the most potent activator
of PI3K signalling due to its multiple binding sites for the PI3K p85 regulatory subunit (7, 8). In
contrast, Eps15 and Cbl are EGFR-specific substrates involved in receptor down-regulation
(9, 10). Importantly, the expressed ErbB receptor repertoire influences the cellular response
4to their ligands. For example, ErbB3 displays increased affinity for HRG when co-expressed
with ErbB2 with ErbB2-overexpressing cells showing a greater response to HRG (11, 12). This
receptor cooperativity has been shown to drive the oncogenic transformation of breast
epithelial cells (13).
Few studies have examined ErbB ligand-specific signalling on a global scale. The aim of this
study was to use proteomics to investigate ErbB ligand-specific responses and signal
diversification downstream of ErbB receptors and to test the effects of ErbB2 overexpression
on these responses in a human mammary luminal epithelial cell (HMLEC) model. This model
comprises an SV40 large T antigen-immortalized HMLEC parental cell line derived from flow-
sorted cells from reduction mammoplasty material and a derivative clone stably
overexpressing ErbB2 at levels seen in breast tumours (14). We have previously used this
model to assess the effects of ErbB2 overexpression on the transcriptional, proteomic, specific
signalling and phenotypic responses to HRG1 and EGF stimulation (12, 15-17). HRG induced
the expression of significantly more genes than EGF and in many cases the response was
elevated in the ErbB2-overexpressing cells; a likely consequence of the higher expression and
preferred heterodimerzation of ErbB2 and ErbB3 in these cells. Despite this, HRG-induced
expression was generally of a lower magnitude than for EGF-induced expression, although it
was often sustained. This is consistent with our previous finding that HRG-dependent
mitogenic signalling is sustained in these cells (16). Gene products involved in regulating the
cytoskeleton, cell adhesion and motility were also identified that were up-regulated by growth
factor treatment to a greater degree in the ErbB2-overexpressing cells. These are likely to
promote the ErbB2-mediated anchorage-independent growth and reduced cellular adhesion
previously observed in this cell model (17).
The present study builds on these findings by utilising more in-depth proteomic and
phosphoproteomic profiling to evaluate the effects of ErbB2 amplification on global protein
expression and signal transduction in response to triggering with EGFR and ErbB3-specific
ligands using the HMLEC model. Downstream ErbB2 signalling targets and putative sites of
5phosphorylation were identified using a combination of SILAC (stable isotope labelling by
amino acids in cell culture) labelling, phosphopeptide enrichment and LC-MS/MS.
Bioinformatics analysis was used to define the possible biological mechanisms involved in
ErbB2-mediated transformation.
Experimental Procedures
Experimental Design and Statistical Rationale – For protein expression profiling, a
reciprocal duplicate SILAC labelling strategy was used to compare two biological replicates
each of ErbB2 overexpressing cells and control parental cells by Gel LC-MS/MS (Figure 1).
Fifty gel slices from each of two lanes of the reciprocally labelled and mixed samples were
digested and analysed in 100 LC-MS/MS runs. For phosphopeptide comparisons of six
different conditions (+/-ErbB2, +/-EGF and +/-HRG1), a common reference sample
comprising a pool of equal protein amounts from the six different light-labelled cultures was
used in singlet comparisons with each heavy-labelled condition. The six heavy:light mixtures
were digested, separated into 15 fractions by strong cation exchange (SCX) chromatography
and SIMAC phosphopeptide enrichment and the resulting 90 samples analysed by LC-MS/MS
(Figure 1). Data was searched and analysed using MaxQuant and Perseus software as
described below. Proteins were accepted as being significantly up/down-regulated with a
significance B value of <0.05.
Cell culture, SILAC labelling, growth factor, IFN and inhibitor treatment and sample
preparation – The HB4a and C3.6 cell lines (14) were cultured for at least 6 passages in light
(12C6-lysine and 12C614N4-arginine) or heavy (13C6-lysine and 13C615N4-arginine) SILAC RPMI
1640 media (Pierce) supplemented with 10% (v/v) dialysed foetal calf serum (FCS), 2 mM L-
glutamine, 100 µg/mL streptomycin, 100 IU/mL penicillin (Invitrogen), 5 µg/mL insulin and 5
µg/mL hydrocortisone (Sigma-Aldrich Co.) in a humidified incubator at 37˚C with 10% CO2.
The final concentrations of light/heavy lysine and arginine were 0.46 mM and 0.47 mM,
respectively. FCS (50 mL) was dialysed 3 times against PBS (5 L) at 4°C using Spectra/Por®
7 dialysis tubing with a 3,500 Da molecular weight cut-off. The incorporation efficiency of heavy
6isotopes was first confirmed by GeLC-MS/MS analysis of heavy-labelled lysates as described
below.
For growth factor treatments, cells were washed with PBS and subsequently serum-starved
for 48 hrs in SILAC media (light or heavy-labelled, respectively) supplemented with 0.1% (v/v)
dialysed FCS, 2 mM L-glutamine, 100 µg/mL streptomycin, 100 IU/mL penicillin and 5 µg/mL
hydrocortisone. Following starvation, cells were treated with either 4 nM EGF or 4 nM HRG1
(both R&D systems) for 10 min or left untreated, and were then washed in ice-cold PBS and
lysed in 1 mL (per T150 flask) of lysis buffer (8 M urea and 20 mM HEPES pH 8.0)
supplemented with protease inhibitors and the phosphatase inhibitors; sodium orthovanadate
(1 mM), sodium fluoride (1 mM), sodium pyrophosphate (2.5 mM) and -glycerol phosphate
(1 mM) (Sigma-Aldrich). Activation of tyrosine phosphorylation and Erk/MAPK signalling by
growth factor treatment was confirmed by western blotting (see Supplementary Data, Figure
S1).
Unlabelled, serum-starved cells were also treated with IFN (1000 IU/mL; PBL Biomedical
Laboratories) or IFN (1000 U/mL; R&D Systems) alone or in combination with either growth
factor (as above) for 24 hrs to test the effect of growth factor on IRF9/ISGF3G induction.
Inhibitor pre-treatments (1 hr) were also tested: ErbB receptor kinase inhibitor AG1478
(Biosource) was used at 5 M, MEK inhibitor PD098059 (Calbiochem) was used at 10 M,
proteasome inhibitor PS341 (Millenium Pharmaceuticals) was used at 1 M and protein
synthesis inhibitor cycloheximide (CHX; Sigma) was used at 10 g/mL.
For determination of protein expression differences between HB4a and C3.6 cells, equal
amounts of protein from C3.6 0, EGF and HRG (heavy pool) or HB4a 0, EGF and HRG treated
cells (light pool) were combined. Pools were mixed 1:1 heavy:light (C3.6:HB4a) and 200 g of
protein (per experiment) resolved by SDS-PAGE on 10% gels. Gels were fixed and stained for
1 hr with InstantBlue Coomassie stain and bands (50 per lane) were excised for in-gel protein
digestion. The above experiment was replicated with reversed labelling to minimise isotope-
specific bias. In-gel digestion was carried out essentially as described (18) and samples
7subjected to clean-up using ZipTipC18 tips (Merck Millipore) according to the manufacturer’s
instructions.
Phosphoproteomic analysis - A sequential strong cation exchange (SCX), immobilised
metal ion affinity chromatography (IMAC) and titanium dioxide (TiO2) strategy linked to LC-
MS/MS (19) and incorporating the SIMAC strategy (20) was used to enrich phosphopeptides
from mixtures of heavy and light SILAC-labelled HMLEC lysates for quantitative comparison
of the effects of different growth factors and ErbB2 overexpression on the phosphoproteome.
Equal amounts of protein from all 6 light-labelled treatment conditions (C3.6/HB4a 0, EGF and
HRG) were pooled and served as a common reference sample to enable inter-experimental
comparison. Protein from each heavy-labelled treatment condition (C3.6/HB4a 0, EGF or
HRG) was mixed separately with a light-labelled common reference pool. The mixed lysates
were diluted to a final concentration of 2 M urea and protein concentrated in 5 kDa molecular
weight cut-off ultrafiltration spin columns. Proteins were reduced at 10 mM DTT for 45 min at
30°C, alkylated with 120 mM iodoacetamide and digested with 100 µg of porcine modified
trypsin at 37°C for 16 hrs. Samples were desalted, dried and resuspended in SCX loading
buffer (5 mM ammonium acetate, 25% ACN, 0.1% FA) and fractionated by SCX (Macro-Prep
High S Support; BioRad) into 5 fractions by batch-wise elution: flow-through, 15 mM, 30 mM,
60 mM and 300 mM ammonium acetate. Fractions were desalted by SPE (Oasis, Waters),
dried and resuspended in loading buffer (50% ACN, 0.1% TFA) for IMAC phosphopeptide
enrichment using Ni3+-Sepharose 6 Fast Flow resin (GE Healthcare) re-charged with Fe3+.
Beads were re-suspended to a 50% (w/v) slurry with IMAC loading/wash buffer and incubated
with the 5 SCX fractions (300 µL per SCX fraction) for 30 min at room temperature. Beads
were centrifuged at 1000 g for 5 min and the flow-through collected. Beads were subsequently
washed, centrifuged and the wash combined with the flow-through (fraction 1). Mono-
phosphorylated peptides were eluted by incubation with 20% (v/v) ACN and 1% (v/v) TFA for
5 min and the eluent collected by centrifugation (fraction 2). Multiply phosphorylated peptides
were eluted sequentially by incubation twice with 1.5% (v/v) ammonium hydroxide (pH 11.3)
in water and then with 2.5% (v/v) ammonium hydroxide in 50% (v/v) ACN. Each elution
8incubation was for 5 min at room temperature and eluents were collected by centrifugation,
combined and acidified to a final concentration of 10% (v/v) FA (fraction 3). Fractions were
lyophilised in a SpeedVac and fraction 3 was stored at -20°C. Phosphopeptides were further
enriched from IMAC fractions 1 and 2 with TiO2 Titansphere 5 m beads (GL Sciences Inc.).
Beads were washed twice in TiO2 loading buffer (1 M glycolic acid, 80% (v/v) ACN and 5%
(v/v) TFA) to minimise their capacity to interact non-specifically with acidic peptides.
Lyophilised fractions 1 and 2 were re-suspended in TiO2 loading buffer containing 40 mM urea
and 0.015% (w/v) SDS. Fractions were incubated with TiO2 beads (10 µL per fraction) for 30
min at room temperature, beads were centrifuged at 1000 g for 5 min and the supernatant was
discarded. Beads were washed sequentially first with loading buffer, then with washing
solution A (80% (v/v) ACN and 5% (v/v) TFA) and finally with washing solution B (10% (v/v)
ACN). Peptides were eluted by incubation with 1.5% (v/v) ammonium hydroxide (pH 11.3) and
then with 30% (v/v) ACN for 5 min at room temperature. Eluants were collected by
centrifugation, combined and acidified to a final concentration of 10% (v/v) FA. Fractions were
lyophilised in a SpeedVac and stored at -20°C.
Liquid chromatography tandem mass spectrometry (LC-MS/MS) – Phosphopeptide-
enriched fractions and gel bands were analysed by LC-MS/MS on an LTQ Orbitrap XL
connected to an Ultimate 3000 nLC system (Thermo Fisher Scientific). Samples were injected
onto an Acclaim PepMap100 C18 pre-column (5 µm, 100 Å, 300 µm i.d. x 5 mm) and washed
for 3 minutes with 90% buffer A (H2O and 0.1% (v/v) FA) at a flow rate of 25 µL/min. Reversed-
phase chromatographic separation was performed on an Acclaim PepMap100 C18 Nano LC
column (3 µm, 100 Å, 75 µm i.d. x 25 cm) with a linear gradient of 10-50% buffer B (ACN and
0.1% (v/v) FA) at a flow rate of 300 nL/minute. The length of the gradient was 40 minutes for
protein expression determination and 90 minutes for the phosphopeptide analysis. Survey full
scan MS spectra (from m/z 400-2000) were acquired in the Orbitrap with a resolution of 60,000
at m/z 400. The mass spectrometer was operated in the data-dependent mode selecting the
6 most intense ions for CID. For phosphopeptide analysis, multi-stage activation for neutral
loss of masses 97.97, 48.985 and 32.65667 was enabled. Target ions selected for MS/MS
9were dynamically excluded for 60 sec. For accurate mass measurement, the lock mass option
was enabled using the polydimethylcyclosiloxane ion (m/z 455.12003) as an internal calibrant.
All MS data have been deposited to the ProteomeXchange Consortium via the PRIDE (21)
partner repository with the dataset identifier PXD004195. Phosphopeptide data retaining the
highest scoring peptide for any given peptide, modification and precursor charge combination
can be viewed using MS-Viewer (22), part of the Protein Prospector Web package, using
search key g2tzikzhsk.
Data analysis and quantification - Acquired mass spectra from heavy-labelled samples were
first processed using Mascot Distiller V2.3.2 (Matrix Science Ltd.) and searched against the
human IPI database V3.72 (86,392 sequences) to determine SILAC label incorporation
efficiency and extent of metabolic conversion of arginine to proline. Enzyme was set as trypsin
(K/R), MS tolerance was set to 10 ppm, fragment MS/MS tolerance was 0.5 Da, 1 missed
cleavage was allowed, carbamidomethylation of cysteine was set as a fixed modification and
oxidation (methionine), acetylation (protein N-terminal), deamidation (asparagine and
glutamine), 13C6 lysine (Lys6), 13C615N4 arginine (Arg10) and 13C515N1 proline (Pro6) were set
as variable modifications. Mudpit scoring was enabled and peptides were required to score
≥20 with a Mascot significance threshold of P<0.05 and were required to be bold red.
All spectra were then processed and analysed using MaxQuant V1.1.1.25 (23) and
searched against human IPI database V3.77 (89,422 sequences + 248 known contaminants)
and a concatenated IPI database for determination of FDR using the Andromeda search
engine (24). Parameters used were as above except that MS tolerance was set to 6 ppm, 2
missed cleavages were permitted and minimum peptide length was 6 amino acids. Spectra
resulting from heavy or light-labelled peptides were submitted to the database search
independently with heavy spectra searched with the Lys6 and Arg10 labels set as additional
fixed modifications, whilst undetermined spectra were searched with the labels set as variable
modifications. For the phosphopeptide analyses, 3 missed cleavages were permitted and the
variable modifications carbamylation (peptide N-terminal) and phosphorylation (serine,
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threonine or tyrosine) were also included. Identified peptides were filtered with an FDR of 1%
using the posterior error probability. Whenever the set of identified peptides in one protein was
equal to or contained the set of peptides identified in another, these two proteins were joined
together as a protein group. According to Occam’s razor principal, shared peptides were most
parsimoniously associated with the protein group containing the highest number of peptides
(razor peptides), but remained in all groups where they were identified. Proteins were required
to contain at least two peptides, of which one was group unique. Peptide ratios were calculated
as the median of all evidences of a SILAC peptide pair and were normalised to correct for
unequal protein loading so that the median of the logarithmised ratios was 0. This was
performed separately for lysine and arginine-labelled peptides and for each LC-MS/MS run.
Protein ratios were calculated as the median of normalised razor and unique peptides and a
minimum of 3 ratio counts were required for quantification. The significance of differential
protein expression was determined using Perseus software V1.1.1.21 (Max-Planck Institute of
Biochemistry, Germany). Proteins were accepted as being significantly up/down-regulated
with a significance B value of <0.05.
Phosphorylation sites were assigned with a modified version of the post-translational
modification (PTM) score (25) and filtered with a site FDR of 1%. The top scoring site for each
peptide was matched to known substrate consensus sequence motifs recognised by specific
kinases. Phosphosites were grouped into one of 3 categories given their PTM localisation
probability and predicted kinase motifs. Class I phosphorylation sites (high confidence) had a
localisation probability of ≥0.75. Class II sites had a localisation probability of 0.5-0.74 and also 
matched a kinase motif. Class III sites had the same localisation probabilities as class II, but
were not predicted to match a kinase motif.
Bioinformatics analysis – Hierarchical clustering and principle component analysis of
significantly differentially expressed gene products (significance B <0.05 and fold-change
>1.5) was carried using Genesis software V1.7.6 (26). Gene ontology (GO) enrichment
analysis was performed using the Cytoscape plug-in BiNGO V2.43 (27) using a
hypergeometric test with a Benjamini-Hochberg correction. Differentially regulated
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phosphopeptides (≥1.5-fold change) were also analysed for over-representation of GOSlim 
terms. Functional pathway analysis was performed using Ingenuity Pathway Analysis
(Qiagen). Differentially expressed proteins were mapped onto protein-protein interaction
networks using the STRING database V9.0 (28) and were required to interact with an
intermediate confidence score ≥0.55 and only with each other. The interaction network was 
imported into Cytoscape for visualisation and analysis. Densely-connected clusters were
identified using the MCODE V1.2 algorithm (29) and clusters with score ≥4 were further 
analysed for enriched GOSlim terms using BiNGO. The NetworKIN algorithm (30) was used
to predict specific kinases for the differentially regulated phosphopeptides (≥1.5-fold change) 
with a site localisation probability of ≥0.75. Phosphosites were matched to the Phosphosite 
Plus and Phosida databases to examine novelty.
Western blotting and qRT-PCR – The protein expression of selected candidates was verified
by western blotting according to standard procedures using specific antibodies (see
Supplementary Data; Table S1) that were detected with HRP-conjugated secondary
antibodies and enhanced chemiluminescence (Perkin Elmer). Real time qRT-PCR was used
to determine IRF9 mRNA expression in HMLECs following IFN and IFN plus EGF treatment.
Total RNA was extracted from cells using TRIZOL reagent (Gibco-Invitrogen) according to the
manufacturer’s instructions. 2.5 g of total RNA was used for reverse transcription using
random hexamer primers (Applied Biosystems) and Superscript II reverse transcriptase
(Invitrogen Life Technologies) following the manufacturer’s protocol and real time qRT-PCR
was carried out using a TaqMan Gene Expression Assay specific for IRF9 (Applied
Biosystems). Reactions were run on an ABI Prism 7700 sequence detection system using
standard cycling conditions. Ct values were determined and the standard curve method using
the HB4a control sample as calibrator and endogenous 18S mRNA as control, used to
calculate mRNA expression relative.
Viral protection assays - A549 cells were seeded into 24-well plates at 2x105 cells/well and
incubated overnight at 37°C. The media was replaced with ‘neat’ or serially diluted conditioned
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media from randomly growing HB4a and C3.6 cells. After 18 hrs, cells were challenged with
encephalomyocarditis virus (0.3, 3, or 10 PFU/cell). At 29 h post-infection, cells were fixed with
formal saline and stained with Giemsa for viable cells. The assay was calibrated using a serial
dilution of Wellferon, a highly purified mixture of Type I IFNs.
Results
ErbB2-dependent protein expression changes – SILAC GeLC-MS/MS analysis was used
to assess global protein expression changes between parental HB4a and ErbB2-
overexpressing C3.6 HMLECs using a duplicate reciprocal labelling strategy. SILAC heavy
labelling efficiency was determined to be >99% with only ~2% of filtered peptides containing
any heavy-labelled proline. Metabolic conversion of arginine to proline was therefore
considered to be negligible for the purposes of quantification. A total of 2,603 unique protein
groups were identified across the replicate experiments with 1,975 protein groups common to
both experiments of which 1,726 (87%) were quantified (see Supplementary Data Table S2
for complete list of proteins identified and quantified per experiment). Linear regression
analysis of normalised protein abundance ratios common to both experiments demonstrated
that the biological replicates were highly reproducible (r2=0.94) (Figure 2A). The average CV
between normalised peptide ratios common to both experiments was 14% (range 0-141%).
The significance of differential protein expression was determined using Perseus software and
is visualised in plots of normalised protein ratio against summed peptide intensity (Figure 1B).
157 unique protein groups common to both experiments had significance B values of <0.05,
with 59 of these highly significant according to a conservative Benjamini-Hochberg correction
(Table S3). Protein ratios were also compared to mRNA ratios taken from a previous
microarray dataset (12). An r2=0.57 indicated a low correlation between protein and mRNA
expression changes between the cell lines (Figure 1C). This is suggestive of a significant
degree of protein expression regulation at the post-transcriptional level and reinforces the
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importance of proteomic analysis over gene expression analysis for investigating the
molecular mechanisms that determine cell behaviour.
Biological functions were assigned to the 157 differentially regulated proteins from UniProt
(Table S3). Predominant amongst the ErbB2-dependent up-regulated gene products were
cytoskeletal and actin-binding proteins including; ACTG1, CAP1, CAPN2, FLNC, KRT4, KRT5,
KRT6A, KRT13, LCP1, MPRIP, PLS1, PLS3, RAI14, RDX, SDCBP, TAGLN, TPM1 and ZYX.
Up-regulated gene products with roles in promoting apoptosis (PDCD4, PDCD6, PKM2,
PRKRA, TP53I3 and UACA) were also frequent, although up-regulated anti-apoptotic proteins
(ACAA2, ANXA4 and YWHAZ) were also evident. CUL4B, LMO7, NEDD4, UBE2H and
proteasomal subunits PSMB5 and PSMB6 with roles in ubiquitination and proteasomal
degradation were also increased in response to ErbB2 overexpression, as well as those
involved in vesicle-mediated transport, endo/exocytosis and receptor recycling, including
ANXA2, COPG2, CPNE3, NSF, RAB2A, SNX1, TNPO3, VPS13C and VPS4B. Other up-
regulated proteins of interest with possible roles in regulating breast tumour cell progression
included DPYSL2, FAM129B, IL18, NDRG1, NME1 and SERPINB5.
Gene products down-regulated in the ErbB2 overexpressing cells were less functionally
diverse. Particularly conspicuous, was the down-regulation of numerous products of interferon
(IFN)-stimulated genes (ISGs) or those involved in IFN-mediated signalling, the cellular
response to IFN or host response to viral infection. These were ASS1, EIF2AK2, ERAP1,
HSPD1, IFI35, MX1, NMI, PSME1, PSME2, PSMB8, PSMB9, SAMDH1, SOD2, STAT1,
STAT2 and WARS. Five of these ISGs are components of the immunoproteasome, involved
in antigen processing for presentation. These subunits replace PSMB5, PSMB6 and PSMB7
when the proteasome switches to the immunoproteasome, and notably all three of these
proteins were conversely up-regulated in the C3.6 cells (Table S3). There were several down-
regulated gene products with roles in DNA replication and DNA damage repair including
NASP, RUVBL2 and the DNA replication licensing factors MCM2, MCM4, MCM6 and MCM7.
Proteins involved in cell-cell and cell-matrix adhesion were also down-regulated, including
BCAM, ICAM1, ITGA6 and ITGB4. Other down-regulated proteins of interest with potential
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roles in regulating ErbB2-dependent transformation included FSCN1, HTRA1 and the tumour
suppressor TP53.
Hierarchical clustering revealed three and four main clusters of up- and down-regulated
proteins, but apart from a sub-cluster containing the four DNA replication licensing factors,
there was no obvious grouping of biological functions (Figure S2). Gene Ontology (GO)
enrichment analysis also proved to be ambiguous for this relatively small set of gene products,
although enrichment of DNA replication and cell cycle regulation were apparent, including
proteasomal-dependent regulation of the G1/S phase transition DNA damage checkpoint (see
Table S4). Nucleosomal assembly and organisation, regulation of apoptosis and immune
response were also enriched. Separate analysis of up- and down-regulated gene products
revealed no significant enrichment of biological processes for the up-regulated set, although
cytoskeletal organisation and actin-binding were enriched molecular functions. Mapping the
differentially expressed proteins to canonical pathways revealed several interlinked pathways
with roles in immune response to viral infection, including the IFN signalling, antigen
presentation, virus entry via endocytosis and the EIF2AK2/PKR-induced IFN and antiviral
response pathways (see Table S5). Gene products with roles in protein ubiquitination, amino
acid metabolism and endocytosis were also over-represented.
Differentially expressed proteins were mapped to the STRING interaction database and
four densely connected clusters were identified (Figure 3). Cluster 1 was enriched for gene
products with roles in viral reproduction, including proteasomal subunits PSME1, PSME2,
PSMB5, PSMB6, PSMB8 and PSMB9, components of the IFN signalling pathway and several
ISGs. Cluster 2 was enriched for nucleoplasmic proteins with roles in cell cycle regulation and
proliferation, including DUT, NASP, MCM2, MCM4, MCM6 and MCM7. Clusters 3 and 4 were
connected by ACAT1 which is involved in amino acid, ketone body and lipid metabolic
processes. Cluster 4 was enriched for components of the mitochondrial electron transfer chain
including ETFA and ETFB. The tumour suppressor TP53 connected clusters 1, 2 and 4. The
large number of edges connecting TP53 likely reflects the extensive amount of knowledge of
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this particular gene product. Clusters 1 and 2 were enriched for down-regulated proteins, whilst
clusters 3 and 4 primarily contained up-regulated proteins.
Western blotting for NDRG1, NME1, PKM2, SERPINB5, TAGLN and ZYX confirmed the
up-regulation of these proteins in the C3.6 ErbB2-overexpressing cells, whilst TP53, MCM2,
MCM4, MCM6, MCM7, NMI, STAT1, STAT2, BCAM, ITGA6 and ITGB4 expression were
confirmed as down-regulated (Figure 4). The relative expression levels of EGFR, ErbB2 and
ErbB3 were also assessed to aid in data interpretation.
Exploration of the mechanism of interferon-stimulated gene (ISG) down-regulation – We
wanted to address the possible mechanisms by which ErbB2 may suppress ISG expression.
We focused on IRF9/ISGF3G as a key IFN-induced gene which associates with the
phosphorylated and activated STAT1-STAT2 dimer to form the transcription factor complex
ISGF3G that binds to IFN-stimulated response elements in target ISGs and triggers their
expression to drive cells into an antiviral state (31). We had also previously observed an
inverse correlation between IRF9 and ErbB2 expression in a panel of breast tumour cell lines
(17). IRF9 protein expression was confirmed as down-regulated in the ErbB2-overexpressing
C3.6 cells, although was inducible by treatment with either IFN (Type I) or IFN (Type II)
treatment, indicating that the cells have an intact IFN signalling pathway (Figure 5A). IRF9
expression was relatively unaffected by EGF or HRG treatments alone, but co-treatment with
IFN and either growth factor, significantly reduced IFN-induced expression in the C3.6 cells.
This growth factor-mediated abrogation was not apparent at the mRNA level (Figure 5B),
suggesting a post-transcriptional mechanism of regulation. This effect was found to be ErbB
receptor-dependent, as cells pre-treated with the ErbB kinase inhibitor AG1478 restored the
ability of IFN to induce IRF9 in the presence of growth factor (Figure 5C). Pre-treatment with
the MEK inhibitor PD098059 also partially restored IRF9 expression. Inhibition of protein
translation with cycloheximide blocked IRF9-induction as expected, as did pre-treatment with
the proteasome inhibitor PS341. Decreased IRF9 expression with PS341 treatment was
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confirmed in both IFN-treated C3.6 cells and over a time course in randomly growing HB4a
cells (Figure 5D).
Immunofluorescence staining of IRF9 and STAT1 in cells treated with IFN or IFN and
growth factor showed no differences in cellular localisation between HB4a and C3.6 cells with
the staining intensity consistent with immunoblotting data for both proteins (data not shown).
There was equivalent STAT1 re-localisation to the nucleus in both cell lines following IFN or
IFN treatment, irrespective of co-treatment with EGF. Basal IRF9 expression was unaffected
by cell confluency or serum withdrawal and neither of the cell lines were found to secrete
IFN using a sensitive viral protection assay (data not shown).
Phosphoproteomic analysis of ErbB-dependent signalling - The present study also aimed
to characterise ErbB signalling events involved in early breast cancer development by
comparative phosphoproteomic analysis of HMLECs triggered with EGFR and ErbB3-specific
ligands in the context of ErbB2 overexpression. A common reference sample pooled from light-
labelled cells was used to enable cross-comparison of enriched phosphopeptides from heavy-
labelled HB4a and C3.6 cells that had been serum-starved or treated with EGF and HRG1.
A total of 2,232 phosphopeptide evidences were identified across the 6 experimental
conditions of which 1,907 (85%) were quantified. Most peptides (98%) were singly
phosphorylated and the phosphoamino acid distribution (pS 80.6%, pT 18.9% and pY 0.5%)
was consistent with previous reports. Phosphosites were localised and grouped into one of 3
categories based on localisation probability and predicted kinase motif. SILAC pair evidences
contained a total of 1,069 phosphorylation sites with localisation probability of ≥0.5, of which 
925 were localised with high confidence (class I). This equated to 381 unique phosphorylation
sites within 280 peptide sequences (219 proteins) across the 6 conditions (see Table S6 for
detailed list of phosphosites and quantification per condition). Sequence-specific database
searching confirmed that no novel sites of phosphorylation were identified. Altered
phosphopeptides (≥1.5-fold change between conditions) were categorised depending on their 
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response to growth factor and/or ErbB2 over-expression (Tables 1A and B). This represented
a total of 289 changes for 113 unique phosphosites in 93 sequences (from 74 proteins) across
the 6 conditions. Hierarchical clustering showed no prominent clusters of the altered
phosphopeptides, although the different types of comparison (growth factor, cell line) did
cluster together (Figure S3). ErbB2-dependent phosphosite ratios (C3.6/HB4a) were
normalised to the protein profiling data when available to account for between cell line
expression differences.
Generally, there was a greater magnitude in the response to EGF versus HRG treatment
for both cell lines (Table 1A). This likely reflects a higher potency of EGF in triggering
downstream phosphotyrosine and ERK1/2 signalling in these cells (16). There were however
a greater number of phosphosites found to be differentially regulated by HRG in the C3.6 cells,
whilst EGF was generally more potent in the parental HB4a cells. This is in accordance with
previous gene expression profiling data (12) and likely reflects the relative levels of ErbB
receptor expression in the two cell lines (Figure 4). There were a similar number of differential
phosphorylation events found in response to EGF and HRG with ErbB2 over-expression,
although growth factor specificity was evident (Table 1B). For example, phosphorylation of
CTTN S417 and S418 were more potently induced by HRG versus EGF when ErbB2 was
overexpressed, as were phosphorylation of AKAP12 T285 and S286. There were several
phosphosites that appeared to be differentially regulated with ErbB2 over-expression, although
these differences were no longer apparent after normalisation for differences in protein level
(e.g. HIST1H1E pT18, RRM2 pS80 and STMN1 pS38) (Table 1B). Conversely, some ErbB2-
dependent differential phosphorylation was only apparent when protein level changes were
taken into consideration (e.g. IRS2 pS917 and STMN1 pS16 and pS25). This highlights the
importance of performing parallel protein expression profiling alongside phosphoproteomic
analysis in order to identify false positives and negatives.
Growth factor- and ErbB2-dependent sites were compared to existing phosphoproteomic
datasets. A total of 50 sites that were previously not known to be regulated by ErbB growth
factor treatment and/or ErbB2 overexpression were identified, including sites on AHNAK,
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CTNNB1, CTTN, EPN1, HDAC7, HNRNPK, IRS2, RGC32 and SEC16A (Table 1A and B),
whilst other sites, particularly those induced by EGF, were confirmed from other studies, for
example (32). Prediction of the specific kinases responsible for targeting the differentially
phosphorylated sites revealed the kinases AURORA, CDK1, CDK2, CK1/2, CAMK2, GSK3B,
MAPK1, MAPK8/JNK1, MAPK10/JNK3, PRKACB and RPS6KA1 to be frequent across the
dataset, although there was little overlap between the NetworKIN and MaxQuant kinase
predictions (Table S7). There was no obvious grouping of kinases between up- and down-
regulated phosphosites or across different experimental conditions, likely reflecting the
complexity of the ErbB receptor signalling network. GO enrichment analysis for phosphosites
differentially regulated by ErbB2 over-expression and EGF stimulation were primarily enriched
for chromosomal and chromatin-binding proteins, whilst those differentially regulated by ErbB2
overexpression and HRG stimulation were also enriched for cytoskeletal proteins. No
biological processes were enriched.
Discussion
We have identified proteomic changes associated with ErbB2 overexpression in a relevant
HMLEC model and characterised in parallel the early phosphorylation events triggered by
ErbB-receptor-specific ligands in the context of ErbB2 overexpression. The identified protein
changes confirm data from our previous proteomic and transcriptional profiling of this cell
model (12, 15, 17, 33) and comparison of gene and protein expression datasets allowed the
identification of proteins that are either transcriptionally or post-transcriptionally regulated in
response to ErbB2 overexpression. The correlation between altered protein and mRNA levels
was similar to a previous study investigating a cell model of brain metastatic breast cancer,
suggesting that there may generally be a correlation factor close to 0.6 between protein and
mRNA in breast epithelial cells (34). Notably, some of the same proteins were altered, possibly
implicating their involvement in the molecular mechanisms by which ErbB2-overexpressing
breast tumours metastasise to the brain. Confirmed up-regulated proteins included AKR1B1,
ALDH1A3, ANXA2, CPNE3, HIBCH, KRT6A, KRT13, LCP1, NME1, PLS3, RDX, SERPINB5,
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TAGLN and ZYX, and down-regulated proteins included ALDH1A1, FKBP4, HSPD1, MCM7,
MX1, SERPINH1, SOD2, STAT1, TXNDC4, USP14 and WARS. Predominant amongst the
deregulated proteins were cytoskeletal, actin binding and cell adhesion proteins with LCP1
(plastin 2) showing the largest fold-change in expression in the dataset. These changes
support observations that ErbB receptor overexpression results in remodelling of the actin
cytoskeleton, altered cell adhesion and increased motility and invasiveness (35). The down-
regulation of the cell adhesion proteins BCAM, CLDN1, ICAM1, ITGB4, ITGA6 and LAMA5
particularly, correlate with the reduced adhesive phenotype displayed by the C3.6 cells (17).
Indeed, LAMA5 is the major laminin -chain of adult epithelial basal laminae and BCAM is its
receptor. The integrin 6/4 (ITGA6/ITGB4) is also a receptor for laminin in epithelial cells and
plays a critical structural role in hemidesmosomes. It is tempting to speculate that hyper-
activated ErbB signalling in HMLECs may promote de-adhesion from the basement membrane
through the reduced expression of these adhesion partners and breakdown of
hemidesmosomes, which in turn may promoting invasiveness. The up-regulation of the
numerous actin-binding proteins may be an adaptation to this lowered adhesive capacity, and
also enable the generation of a more motile phenotype. Enhanced detachment may in turn up-
regulate the observed pro-apoptotic proteins, although they appear not to trigger apoptosis
under normal growth conditions; the hyper-proliferative phenotype of the C3.6 cells (14, 16),
would argue that these proteins are not active and so may fulfil alternative roles.
Down-regulation of the DNA replication licensing factors MCM2, MCM3, MCM4, MCM6 and
MCM7 is curious in this setting, since they are part of the replicative helicase complex essential
for 'once per cell cycle' DNA replication and the C3.6 cells have been shown to be more
proliferative with a shortening of the G1 phase of the cell cycle and early S phase entry (16).
We propose that their down-regulation in the ErbB2 overexpressing cells may be a feedback
mechanism that responds to a hyper-proliferative phenotype.
The observed constitutive down-regulation of numerous IFN-inducible genes, including
components of the immunoproteasome, suggests that ErbB2 overexpression may suppress
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basal IFN-mediated signalling (and perhaps antigen presentation) in HMLECs. Since ISGs
inhibit proliferation and promote apoptosis, this suppression of ISGs may be a mechanism
whereby ErbB2 promotes transformation of HMLECs. We provide evidence that the
suppressed expression of components of the transcriptional activator complexes induced by
IFN and IFN (i.e. STAT1-STAT2-IRF9 and STAT1-STAT1, respectively) is likely to be the
upstream event accounting for the observed ‘global’ suppression of ISG expression. Down-
regulation of the IFN-stimulated N-myc interactor (NMI) is also interesting in this context, as
it is known to augment cytokine-mediated STAT transcription (36). Expression of the tumour
suppressor TP53 was also down-regulated in the C3.6 cells and may contribute to the
transformed phenotype. TP53 down-regulation may be a consequence of impaired IFN
signalling, since it is known to be induced by IFN (37). Finally, the down-regulation of
HSPD1 and IRF3 may be expected to reduce autocrine IFN production. However, neither
cell line was found to secrete IFN, so their altered secretion cannot explain the observed
alteration in basal IFN signalling.
Our data show that whilst both IFN and IFN induce the expression of IRF9 in the ErbB2
overexpressing cells, co-stimulation with EGF or HRG1 reduced IFN-mediated induction of
IRF9 without altering STAT1 activation or IRF9 mRNA levels and which we show to be ErbB
kinase-dependent. This demonstrates a direct post-transcriptional effect of ErbB receptor
signalling on IRF9 expression and hence reduced IFN signalling. Intriguingly, the induction
and basal expression of IRF9 was reduced by proteasomal inhibition in this cell model. We
therefore propose that there may be a negative regulator of IRF9 protein stability, which is
itself a rapidly turned over protein targeted by the proteasome. We speculate that this regulator
is activated or stabilised through downstream ErbB2 signalling to result in IRF9
downregulation. Whether or not the repressed immunoproteasome observed in the ErbB2
overexpressing cells has a role to play in such a mechanism remains to be determined, as
does the identity of the proposed IRF9 regulator. In summary, we provide a possible
mechanism by which oncogenic signalling leads to impaired IFN signalling that has been
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reported in various cancer types. Immune-response related gene signatures with prognostic
value have been frequently found in breast tumour studies. One recent study found an
increased expression of an ISG metagene (including gene products found herein) that was
associated with a lower risk of metastasis in ErbB2+ tumours (38). We would therefore
propose that ErbB2-mediated down-regulation of IFN signalling may also promote metastasis
and evasion of anti-tumour immunity.
Interpretation of the phosphoproteomic data in terms of providing mechanistic insight into
the processes of cellular transformation is more challenging. Indeed a limitation of the present
study is that quantitative information for each phosphosite across all experimental conditions
was not complete; a consequence of data-dependent acquisition. However, we cannot rule
out the possibility that these ‘missing’ phosphopeptides are bona fide biological differences,
due to the absence or very low levels of the phosphopeptide under those experimental
conditions. Prediction of the kinases involved also proved not to provide meaningful groupings
and was inconsistent between the two prediction approaches used and there was no
enrichment of specific functional groups for the phosphoproteins identified. This is likely to be
a consequence of the complexity of growth factor-mediated phosphosignalling. Despite this,
we have identified numerous novel growth factor-regulated phosphorylation events, identified
different responses to EGF versus HRG1 triggering and showed sites whose phosphorylation
were modulated by ErbB2 overexpression basally and in response to growth factor treatment.
Chromosomal and chromatin-associated phosphoproteins were enriched, indicating that rapid
changes (within 10 min) in the phosphorylation of nuclear proteins occurs in response to
growth factor treatment. The data also suggests that ErbB signalling may modulate chromatin
structure as part of transcriptional programming. Cytoskeletal proteins were also enriched in
the set of proteins differentially modulated by ErbB2 overexpression and HRG treatment,
feasibly linking these phosphorylation events to altered adhesion, motility and invasiveness.
A number of novel ErbB growth factor and ErbB2-dependent phosphorylation sites were
identified including CTNNB1-pS675, CTTN-pT401, CTTN-pS417, EPN1-pS454, HDAC7-
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pS486, HNRNPK-pS116, RGC32-pS97, SEC16A-pS1964 and SEC16A-pS2083. CTNNB1 (-
catenin) is a regulator of cell adhesion and a downstream effector of Wnt signalling. It is
phosphorylated and destabilized by CK1 and GSK3B, with stabilized CTNNB1 reported as a
hallmark of many cancers. CTNNB1-S675 was phosphorylated in response to both growth
factors (at least in C3.6 cells). Phosphorylation of S675 by PKA, PAK1 and/or PAK4 has been
reported to promote CTNNB1 stability and transcriptional activity and we propose that this
occurs in HMLECs in response to promiscuous ErbB signalling.
Several growth factor and ErbB2-regulated phosphorylation sites were identified on CTTN
(cortactin), including novel sites pT401 and pS417. Doubly phosphorylated peptides
containing pT399-pS405 and pS417-pS418 were also identified. The growth factor dependent
down-regulation of the singly phosphorylated T399 peptide was reversed by phosphorylation
at S405, with the doubly phosphorylated peptide more highly induced by HRG in the C3.6
cells. This suggests a novel interaction whereby S405 promotes growth factor-dependent
phosphorylation of T399. The pT401 phosphopeptide showed a similar profile to pT399. The
S417 and S418 singly phosphorylated peptides behaved similarly to one another and were
also increased in HRG-treated C3.6 versus HB4a cells. CTTN is a cytoskeletal protein involved
in coordinating actin reorganization during cell movement and is overexpressed in numerous
cancers where it may contribute to cell invasion. ERK1/2 and PAK1 are known phosphorylate
CTTN on S405 and S418 resulting in localisation of CTNN at sites of dynamic actin assembly
promoting lammelipodial persistence and motility through interaction with WAVE2 and WASL
(39). Our data thus suggest that ErbB signalling may enhance HMLEC motility through its
effect on CTTN phosphorylation.
EPN1 (epsin1) is a regulator of receptor-mediated endocytosis, including EGFR, and its
phosphorylation at S454 in response to EGF and HRG, and augmentation by ErbB2
overexpression, may be a mechanism that attenuates ErbB receptor signalling through
endocytosis. HDAC7 is a core histone deacetylase involved in transcriptional repression.
Phosphorylation of HDAC7 at S486 by PRKD1 in response to VEGF has been shown to result
in nuclear export promoting proliferation, motility and transcription (40). Our findings suggest
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that EGF and ErbB2 overexpression may similarly alter cell behaviour, at least in part through
HDAC7-S486 phosphorylation. HNRNPK is involved in pre-mRNA processing and the TP53
response to DNA damage. We propose that its proliferation promoting activity may be
regulated by ErbB-dependent signalling through phosphorylation at S116. Finally, RGC32
modulates the activity of cell cycle-specific kinases and its novel growth factor and ErbB2-
dependent phosphorylation at S97 may contribute to cell cycle progression.
In conclusion, we have characterised protein expression changes and phosphorylation
events that occur in response to ErbB2 overexpression and ErbB growth factor triggering in a
relevant cell model of early mammary luminal epithelial cell transformation. The work
demonstrates the complexity of the responses to oncogene expression and growth factor
signalling and we have attempted to put some of the changes into the context of an altered
cellular phenotype, in particular cell cycle progression and hyper-proliferation, reduced
adhesion and enhanced motility. Moreover, we have defined a novel mechanism by which
ErbB signalling suppresses basal IFN signalling that may promote the survival and proliferation
of HMLECs and that may have implications for breast cancer metastasis and treatment. Our
findings may also help in understanding the consequences of dysregulated ErbB2 signalling
in other cancer types where ErbB2 overexpression occurs in a significant proportion of cases.
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Tables
Table 1A Growth factor regulated phosphorylation. 1pST and 2pST refer to singly and doubly
phosphorylated peptide ratios for the indicated sites and experimental comparisons (see text).
Sites shaded grey indicate those not previously known to be regulated by growth factors.
Values in bold show a ≥1.5 fold-change in abundance as determined from SILAC ratios. Dark 
grey is up-regulated, light grey is down-regulated.
HB4a EGF vs.
HB4a 0
HB4a HRG vs.
HB4a 0
HB4a HRG vs.
HB4a EGF
C3.6 EGF vs.
C3.6 0
C3.6 HRG vs.
C3.6 0
C3.6 HRG vs.
C3.6 EGF
Protein Site 1pST 2pST 1pST 2pST 1pST 2pST 1pST 2pST 1pST 2pST 1pST 2pST
AHNAK S210 2.41 1.21 0.5 10.32 2.14 0.21
AHNAK S212 7.34
AHNAK T218 0.67 0.99 1.48 1.01
AHNAK S570 2.03
AHNAK T3716 0.44
AHNAK S5110 3.58 2.83 0.79 1.68
AHNAK S5448 0.63 1.36 2.16 2.09 2.42 1.16
AHNAK S5763 0.58 2.99 1.68 0.56
AKAP12 T285 0.27 0.54
AKAP12 S286 0.24 0.54
AKAP2 S383 1.01 2.87
AKAP2 S624 1.08 1.8 1.6 0.89
BAG3 S377 0.91 1.99 2.19 1.26 1.8 1.44
BAG3 S381 0.65 1.12
BAG3 S385 0.6 1.25
C19orf21 S394 0.65 0.7
CAST S11 0.84 0.67
CCDC6 S244 2.7 1.87 0.69 5.18 3.74 0.72
CTNNB1 S675 1.26 2.2 2.07 0.94
CTTN T399 0.49 3.31 0.7 1.75 1.45 0.53 0.4 0.6 5.16 1.49
CTTN T401 0.41 0.77 1.88 0.37 0.61 1.65 1.02
CTTN S405 4.95 3.31 3.47 1.75 0.7 0.53 34.92 5.08 28.61 5.16 0.82 1.02
CTTN S417 2.29 1.41 0.62 3.59 3.02 0.84
CTTN S418 2.98 1.64 0.55 3.74 3.01 0.81
EGFR T693 3.04 3.33 1.09 1.03
EPN1 S454 2.86 1.99 0.7 4.9 2.79 0.57
FOXK2 S428 1.58
GATAD2B S486 1.92 3.88 2.54 0.66
GIGYF2 S26 1.39 1.61
GIGYF2 S30 1.99 1.69 0.85 1.02
HDAC7 S486 1.36 1.19 0.87 1.55 1.15 0.75
HIST1H1B S18 1.16 0.85 0.73 1.67 2.07 1.24
HIST1H1E T18 1.04 0.86 0.83 1.21 1.5 1.24
HNRNPK S116 0.67 5.03 2.58 0.51
HNRNPK S379 1.31 2.02
JUND S90 0.38 0.64
KIAA1522 S404 1.08 1.53
KLC4 S608 1.5 1.09 0.73 0.7
KRT7 S2 0.67 0.8 1.19
LIMA1 S491 1.32 0.96 0.73 1.7
LRRFIP1 S120 1.54
MARCKS S101 3.08 1.65 0.53 4.26 2.2 0.52
NCOA3 S857 2.1 1.89 0.9 1.85 1.43 0.78
NDRG1 T366 0.96 1.55 1.62 1.54
NUCKS1 S181 1.57 1.17
NUMA1 S1763 2.45 1.62 0.66 0.91
NUP50 S223 0.45 0.62
PDLIM2 S134 0.9 0.44
PDLIM2 S137 7.86 2.76 0.35
PGM1 S117 1.01 0.95 0.94 0.72 0.65 0.9
PHF10 S12 0.84 0.88 1.04 0.65
PLEC S21 0.74 0.76 0.67 0.89
PPP1R13L S187 0.44 0.55
PRRC2A T609 0.76 1.6 1.09 0.68
PRRC2A T610 1.39 1.71
RAVER1 T463 3.62 2.16 0.6 7.9 4.17 0.53
RGC32 S97 6.71 3.29 0.49 8.63
SAMD1 S161 1.61 1.24 0.77 2.13 1.86 0.87
SEC16A S1964 4.04 2.55 0.63 6.43 4.3 0.67
SEC16A S2083 1.68 1.31 0.78 2.16 1.59 0.73
SNX2 T104 0.58 1.01
29
SNX2 T106 0.58
SORBS3 T187 1.74
SORBS3 S188 0.95 1.61
SRRM2 S424 0.58
SRSF11 S207 1.64 2.77
SRSF11 S209 0.61
STMN1 S16 0.49 0.94 1.93
STMN1 S25 10.95 4.26 0.39 0.61
STMN1 S38 1.42 1.25 0.88 1.89 1.75 0.92
TCOF1 S906 0.88 1.51 1.72
TCOF1 S1019 0.72 0.71 0.99 0.66
TFPT T207 1.59 1.32 0.83
TRAFD1 S415 1.59 1.47 0.92
TXLNA S514 2.08 0.95
UBAP2L S453 1.93 2.01 1.04 1.76
UBAP2L S454 1.45 1.33 0.91 1.92 2.03 1.05
USP14 S181 1.58
Table 1B ErbB2-regulated phosphorylation. 1pST and 2pST refer to singly and doubly
phosphorylated peptide ratios for the indicated sites and experimental comparisons. Sites
shaded grey indicate those not previously known to be regulated by growth factors or ErbB2.
Ratios were normalized for changes in protein level between C3.6 and HB4a cells where
available. Values in bold display ≥1.5 fold-change in abundance as determined from SILAC 
ratios. Dark grey is up-regulated, light grey is down-regulated.
C3.6 0 vs. HB4a 0 C3.6 EGF vs. HB4aEGF
C3.6 HRG vs. HB4a
HRG
Protein Site
Ave Protein
Ratio C3.6 vs.
HB4a 1pST 2pST 1pST 2pST 1pST 2pST
AHNAK S135 1.37 1.78 1.3
AHNAK S210 1.37 0.52 2.24 0.93
AHNAK S212 1.37 0.28
AHNAK S216 1.37 1.15
AHNAK T218 1.37 1.4 0.95
AHNAK S220 1.37 1.61
AHNAK S5110 1.37 0.52 1.11
AHNAK S5448 1.37 0.41 1.37 0.73
AHNAK S5763 1.37 1.27 1.23
AKAP12 T285 1.2 1.12 2.26
AKAP12 S286 1.2 1.22 2.76
AKAP12 S598 1.2 1.36 1.18 1.17
AKAP12 S1395 1.2 1.92
BAG3 S381 1.27 0.79 1.38
BAG3 S385 1.27 0.77 1.59
C19orf21 S394 2.92 0.6
C9orf142 S148 0.94 0.7 0.84 0.65
CCDC6 S244 1.59 0.93 1.78 1.86
CFL1 S3 1.2 0.52 0.57 0.52
CTNNB1 S675 1.01 0.4 0.66
CTTN T399 0.8 1.13 0.69 0.92 0.96 2.03
CTTN S405 0.8 0.15 0.69 1.08 1.06 1.26 2.03
CTTN S417 0.8 0.73 1.14 1.56
CTTN S418 0.8 0.84 1.06 1.55
CXorf26 S197 1.22 1.27 0.91
EGFR S695 0.9 0.75
EPN1 S454 1.1 0.99 1.7 1.39
FOXK2 S398 0.52
GFPT1 S261 0.58 0.37
GIGYF2 S26 0.67 0.83
GTF2F1 T446 0.87 0.7
HDAC7 S486 1.92 2.18 1.86
HIST1H1B T11 1.78
HIST1H1B S18 2.41 3.46 5.89
HIST1H1D T18 2.51 2.98 4.64
HIST1H1E T18 3.54 0.56 0.66 0.97
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HSP90AB1 S255 0.73 1.11 0.8 0.89
IRS2 S915 2.25 0.81 0.58 0.58
IRS2 S1205 2.25 0.75
ITSN1 S904 0.93 2.79 2.57 2.33
JUND S90 1.27 2.15
KRT13 S427 3.82 1.11 1.51 1.62
LMO7 S988 3.74 1.08 1.36
NCOA3 S857 1.75 1.53 1.32
NDRG1 T366 2.07 1.48 1.41
NUCKS1 S181 0.67 0.49
NUMA1 S1763 0.47 0.84 1.16
NUP50 S223 1.12 1.55
PDLIM2 S134 1.88 0.93
PGM1 S117 0.98 0.95 0.68 0.65
PRRC2A T610 0.65 1.02 1.26
PTMS S5 0.64 0.84
RAVER1 S14 0.78 0.8 1.17 0.72
RAVER1 T463 0.78 0.6 1.3 1.15
RGC32 S97 1.25 3.29
RRM2 S80 0.58 0.93 0.92 0.97
RSL1D1 T358 1.73 0.87
RSL1D1 S361 1.73 1.07 0.9
SEPT9 S30 0.78 0.81
SLC9A3R1 S280 1.3 1.38
SOX15 S37 0.85 0.79 0.64
SRRM2 S424 1.09 2.24
SSB S366 0.58 1.39 1.12
STMN1 S38 0.68 0.71 0.95 1
SUMO1 S2 0.47 1.38
TCOF1 S1019 0.94 0.57 0.52
TERF2IP S203 0.9 0.65 0.6
TPI1 S58 1.03 1.67 1.34 1.44
TRIM28 S19 0.65 0.9 1.2 1.1
ZNF185 T204 1.57 1.19
ZNF185 S447 1.57 1.04 1.24
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Figure Legends
Figure 1 Study workflow for protein expression (A) and phosphoproteomic (B) profiling.
Independent cell cultures were reciprocally labelled with heavy and light lysine/arginine as
shown for at least 6 passages. Cells were serum-starved then stimulated with EGF or HRGb1
for 10 min (or left unstimulated) as shown. Cells were lysed and equal amounts of protein were
mixed from each condition and then these mixed to generate reciprocally labelled biological
duplicate pools. These were separated by SDS-PAGE and 50 gel slices per lane (n=100)
excised and digested with trypsin, prior to LC-MS/MS. For phosphoproteomic profiling, a
common reference pool was generated by pooling equal amounts of protein from light-labelled
cultures and this used in singlet comparisons for each heavy-labelled condition. The 6
heavy:light mixtures were digested, separated into 5 SCX fractions and each subjected to
SIMAC phosphopeptide enrichment generating 3 fractions each. Thus, 90 samples were
generated and analysed by LC-MS/MS. Protein identification, phosphosite identification and
SILAC-based quantification were performed for both datasets using MaxQuant software.
Figure 2 (A) Graph showing correlation between normalised protein abundance ratios
common to biological replicate experiments. (B) Plots showing normalised protein abundance
ratios versus ion intensity for each replicate experiment. Individual protein groups are
grayscaled according to significance B value. (C) Comparison of protein expression (SILAC)
and mRNA (microarray) ratios between HB4a and C3.6 cells. Microarray data was taken from
(12)
Figure 3 Protein interaction analysis of significantly up/down-regulated proteins. Significantly
up/down-regulated proteins (significance B <0.05) were mapped to STRING interaction
networks with a confidence score cut-off of 0.55 (intermediate confidence). Up-regulated
gene-products are coloured in dark grey whilst down-regulated proteins are in light grey. The
number of edges per node represents the different types of evidence for the interaction. The
interaction network was imported into Cytoscape and densely connected protein clusters were
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identified using the graph theoretical clustering algorithm MCODE. Clusters with an MCODE
score of 4 were analysed for enriched GOSlim terms using the Cytoscape plugin Bingo as
described. The table lists the top scoring GOSlim term for each cluster.
Figure 4 Western blotting confirmation of differential expression in HB4a and C3.6 cells.
EGFR, ErbB2 and ErbB3 expression were also compared. Actin served as a loading control.
Figure 5 (A) Western blotting showing suppression of IRF9 expression in C3.6 cells that could
be induced by IFN or IFN treatment (24 hrs) and blocked by co-treatment with EGF or
HRG1. CDK4 expression served as a loading control. (B) IRF9 mRNA levels in IFN and
IFN plus EGF (+E) co-treated HMLECs measured by qRT-PCR. (C) IRF9 expression and
ERK signalling in HMLECs treated with IFN and IFN plus EGF with or without pre-treatment
with protein synthesis inhibitor cycloheximide (CHX), MEK inhibitor PD098059 (PD),
proteasome inhibitor PS341 (PS) or ErbB receptor kinase inhibitor AG1478 (AG). CDK4
expression served as a loading control. (D) IRF9 protein expression is decreased by
proteasome inhibitor (PS341) treatment in IFN-stimulated C3.6 cells (upper panel) and
randomly growing HB4a cells (lower panel).
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